Potential mechanism exploration of San Wei Tan Xiang capsule for depression treatment by network pharmacology and molecular docking

San Wei Tan Xiang(SWTX)capsule has been proved to have significant curative effect on depression in clinic and have less side effects in the treatment.Based on network pharmacology,the mechanism of depression treatment by SWTX capsule was studied.The related targets of depression were collected in the GeneCards database.The active ingredients and potential target genes of SWTX were screened out in the TCMSP database,and the chemical formulas of the active ingredients were confirmed in the PubChem database.As a result,Oleic,quercetin,and beta-sitosterol were screened to be the main ingredients correlated with depression.And NCOA2,GABRA1,and RXRA were analyzed to be the main targets of SWTX on depression.Moreover,the results of molecular docking showed that Oleic and quercetin successfully docked with RXRA.Taken together,using the method of network pharmacology,the main active ingredients of SWTX,and its target points and related pathways on depression are initially revealed,which provides a new idea for depression treatment.

A randomized clinical efficacy trial of Hehui capsule against hyperlipidemia

Hehui capsule(Hhc)has been used as an assistant treatment for hyperlipidemia.According to the previous studies,miltiorrhiza and Chavica roxburghii may reduce the serum lipid level.This study aims at examining the efficiency of Hehui capsule with regards to treating hyperlipidemia in a randomized control,double-blind clinical trial.In the research,we assigned 104 eligible subjects to Hehui capsule group and placebo groups(52:52,respectively).Subjects used self-control and inter-group controls to compare serum total cholesterol(TC),triglyceride(TG),high-density lipoprotein cholesterol(HDL)and other changes before and after the test group and the test group and the control group.During the 45 days intervention,101 cases were actually included,among which 51 cases for test group,and other 50 cases for placebo group.The total effective rate of blood lipid reduction(90.20%)in the test group was significantly higher than that in the control group(26.00%)(P<0.01).Together,the result indicates that Hhc has a certain curative effect on dyslipidemia,with no obvious adverse reactions,which can be developed into a new drug for hyperlipidemia.